8-K
filed November 1, 2022, 7:59 PM ET
ticker SABS
CIK 0001833214
other material
confidence high
sentiment positive
materiality 0.70
SAB Biotherapeutics enters exclusive CDMO partnership with Emergent BioSolutions for polyclonal antibodies
SAB Biotherapeutics, Inc.
- Emergent to provide end-to-end cGMP manufacturing services for SAB's fully-human polyclonal antibody products.
- Emergent gets exclusive option to commercial manufacture SAB's products and right of first refusal on three therapeutic areas: botulism, pandemic influenza, anti-fungal.
- SAB's DiversitAb platform uses transchromosomic cows to produce fully-human polyclonal antibodies without human donors.
- Financial terms not disclosed; partnership covers both clinical and potential commercial manufacturing.
Key facts
Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
SAB Biotherapeutics, Inc. entered into Right of First Refusal Agreement with Emergent BioSolutions Canada, Inc. (effective 2022-10-26).
- Action
- entry
- Agreement
- license
- Counterparty
- Emergent BioSolutions Canada, Inc.
- Effective
- 2022-10-26
Exact text from the filing
On October 26, 2022, SAB Biotherapeutics, Inc., a Delaware corporation (the “Company”) entered into a Manufacturing Option Agreement (the “Manufacturing Agreement”) and Right of First Refusal Agreement (the “RoFR Agreement,” and together with the Manufacturing Agreement, the “Agreements”) with Emergent BioSolutions Canada, Inc., a wholly-owned subsidiary of Emergent BioSolutions Inc. (“Emergent”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
SAB Biotherapeutics, Inc. entered into Manufacturing Option Agreement with Emergent BioSolutions Canada, Inc. (effective 2022-10-26).
- Action
- entry
- Agreement
- supply
- Counterparty
- Emergent BioSolutions Canada, Inc.
- Effective
- 2022-10-26
Exact text from the filing
On October 26, 2022, SAB Biotherapeutics, Inc., a Delaware corporation (the “Company”) entered into a Manufacturing Option Agreement (the “Manufacturing Agreement”) and Right of First Refusal Agreement (the “RoFR Agreement,” and together with the Manufacturing Agreement, the “Agreements”) with Emergent BioSolutions Canada, Inc., a wholly-owned subsidiary of Emergent BioSolutions Inc. (“Emergent”).
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.